1-(N,N'-bis{[(2-methyl-2-propanyl)oxy]carbonyl}carbamimidoyl)-4-piperidinecarboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(N,N'-bis{[(2-methyl-2-propanyl)oxy]carbonyl}carbamimidoyl)-4-piperidinecarboxylic acid
• 英文别名: 1-[(E)-N,N'-bis[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]piperidine-4-carboxylic acid
• 化学式: C₁₇H₂₉N₃O₆
• 分子量: 371.434
• InChiKey: OWKXYOAEYHHLCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  118
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(N,N'-bis{[(2-methyl-2-propanyl)oxy]carbonyl}carbamimidoyl)-4-piperidinecarboxylic acid 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 50.0h， 生成 (S)-3-{3-[(1-Carbamimidoyl-piperidine-4-carbonyl)-amino]-4-methoxy-phenyl}-2-(3-trifluoromethyl-benzenesulfonylamino)-propionic acid; compound with trifluoro-acetic acid
  参考文献：
  名称：

  Novel RGD-like molecules based on the tyrosine template: design, synthesis, and biological evaluation on isolated integrins αVβ3/αIIbβ3 and in cellular adhesion tests

  摘要：

  RGD (Arg-Gly-Asp) peptidomimetics have been designed for covalent anchorage on biomaterials. The tyrosine template was thus equipped with (i) a basic side chain of various flexibility, (ii) an acidic side chain, which incorporated the XPS fluorine tag, and (iii) a spacer-arm terminated by a primary amine for surface grafting. The most active compounds showed IC50 values in the nanomolar range versus isolated human integrins alpha(v)beta(3) and alpha(IIb)beta(3). Preincubation of CaCo2 cells with soluble peptidomimetics (2 and 19a) prevented cellular adhesion on culture plates coated with vitronectin. On the other hand, peptidomimetics (19a and 19b) immobilized on a poly(ethylene)terephthalate membrane (PET) promoted CaCo2 cells adhesion. A modeling study at the ab initio level in MINI-1' basis allowed to compare the various synthetic ligands of integrins and to propose novel pharmacophore structures. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.07.055
• 作为产物：
  描述：

  N,N'-bis( tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine 、 piperidine-4-carboxylic acid, trifluoroacetic acid salt 在 三乙胺 作用下， 以 甲醇 为溶剂， 反应 18.0h， 以76%的产率得到1-(N,N'-bis{[(2-methyl-2-propanyl)oxy]carbonyl}carbamimidoyl)-4-piperidinecarboxylic acid
  参考文献：
  名称：

  SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES

  摘要：

  本发明提供了一般式(I)的化合物，及其盐和N-氧化物，以及它们的溶剂合物和前药（其中取代基如描述中定义）。一般式(I)的化合物是因子XIa的抑制剂，并且在预防和/或治疗血栓栓塞疾病方面具有用途。

  公开号：

  US20150152048A1

文献信息

• [EN] SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES<br/>[FR] PYRROLIDINES SUBSTITUÉES COMME INHIBITEURS DU FACTEUR XIA POUR LE TRAITEMENT DE MALADIES THROMBOEMBOLIQUES
  申请人：ONO PHARMACEUTICAL CO

  公开号：WO2013174937A1

  公开（公告）日：2013-11-28

  The present invention provides compounds of the general formula (I), their salts and N- oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供了一般式(I)的化合物，以及它们的盐和N-氧化物、溶剂合物和前药（其中取代基如描述中定义）。一般式(I)的化合物是XIa因子的抑制剂，对预防和/或治疗血栓栓塞性疾病有用。
• Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US09394250B2

  公开（公告）日：2016-07-19

  The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供了一般式(I)的化合物，它们的盐和N-氧化物，以及它们的溶剂合物和前药(其中取代基如描述中所定义)。一般式(I)的化合物是因子XIa的抑制剂，并且在预防和/或治疗血栓栓塞性疾病方面非常有用。
• Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US10336741B2

  公开（公告）日：2019-07-02

  The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供通式（I）化合物、其盐类和 N-氧化物及其溶液剂和原药（其中取代基如描述中所定义）。通式（I）化合物是因子 XIa 的抑制剂，可用于预防和/或治疗血栓栓塞性疾病。
• SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES
  申请人：ONO Pharmaceutical Co., Ltd.

  公开号：EP2855452B1

  公开（公告）日：2017-04-26
• US9394250B2
  申请人：——

  公开号：US9394250B2

  公开（公告）日：2016-07-19